Emerging treatment possibilities in noninfectious ocular inflammation: what's on the horizon?

Abstract

Noninfectious ocular inflammation, particularly uveitis, continues to be a leading cause of visual impairment and blindness globally. Traditionally, the management of these conditions has depended on corticosteroids and immunosuppressive therapies. However, in cases of severe inflammatory ocular disease, it is crucial to balance the benefit of vision preservation against the risk of potentially serious treatment-related side effects, which are often significant and may lead to longterm complications. Recently, novel therapeutic strategies have emerged, bringing renewed hope. Advances in biologic therapies, small molecule inhibitors, and targeted immunomodulators are transforming the management of uveitis. These innovative treatments are designed to reduce inflammation with greater precision, minimize systemic adverse effects, and enhance long-term outcomes. In this presentation, we will explore the potential of these groundbreaking therapies, including IL-6 inhibitors, JAK inhibitors, and other targeted treatments, in shaping the future of patient care.